We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · May 05, 2021

Long-Term Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
J. Clin. Oncol 2021 Apr 23;[EPub Ahead of Print], BM Eyck, JJB van Lanschot, MCCM Hulshof, BJ van der Wilk, J Shapiro, P van Hagen, MI van Berge Henegouwen, BPL Wijnhoven, HWM van Laarhoven, GAP Nieuwenhuijzen, GAP Hospers, JJ Bonenkamp, MA Cuesta, RJB Blaisse, OR Busch, GM Creemers, CJA Punt, JTM Plukker, HMW Verheul, EJ Spillenaar Bilgen, MJC van der Sangen, T Rozema, FJW Ten Kate, JC Beukema, AHM Piet, CM van Rij, JG Reinders, HW Tilanus, EW Steyerberg, A van der Gaast

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading